Firalis

Doing business as Firalis

UEI
KKDHW3ENL7L4
CAGE
FBEE7
Primary NAICS
541714 Research and Development in Biotechnology (except Nanobiotechnology)
SAM.gov registration
Expired

Company facts

Self-certified in SAM.gov
  • For Profit Organization
Entity structure
Corporate Entity (Tax Exempt)
NAICS codes registered in SAM.gov
Corporate family
SAM.gov registration date
Website
firalis.com
Founded
2008
Employees
11-50
Estimated annual revenue
$1M-$10M
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Biotechnology
SIC code
87 Engineering & Management Services
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Recent federal awards

Firalis's 3 most recent federal contract and grant awards, newest first. Amounts are dollars obligated.
Award Agency Obligated Awarded
Mirna whole transcriptome assay (WTA) service in human plasma samples Contract · 75F40122P00293 Food and Drug Administration $52,163
Profiling of microrna transcripts in mouse plasma samples after treatment with sunitinib Contract · 75F40120P00191 Food and Drug Administration $61,545
Profiling microrna transcripts in plasma samples Contract · 75F40119P10307 Food and Drug Administration $161,845

About Firalis

Firalis is a leading biotechnology company specializing in cardiovascular biomarkers and diagnostic tools for preclinical and clinical applications. It is a for-profit corporate entity registered to receive federal awards, with an active registration in the System for Award Management (SAM.gov) until May 2023.

Firalis has received multiple prime contract awards from the Department of Health and Human Services Food and Drug Administration (FDA). These contracts involve providing specialized services related to profiling microRNA transcripts and conducting whole transcriptome assays in plasma samples from humans and mice. The work includes analyzing microRNA expression levels and performing diagnostics on cardiovascular biomarkers. The contracts awarded to Firalis by the FDA are firm-fixed-price purchase orders, with values ranging from around $52,000 to $161,845. The projects do not have any set-aside designations and are not limited to specific socioeconomic categories. The services provided by Firalis support the FDA's research efforts in areas such as drug development and understanding the effects of treatments on biomarkers and gene expression profiles.

Quick answers

What is Firalis's UEI?

Firalis's Unique Entity ID (UEI) in SAM.gov is KKDHW3ENL7L4.

What is Firalis's CAGE code?

Firalis's CAGE code is FBEE7.

What is Firalis's primary NAICS code?

Firalis's primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).

Is Firalis registered in SAM.gov?

Firalis's SAM.gov registration expired on May 19, 2023.

What is Firalis's most recent federal award?

Firalis's most recent federal contract award is Mirna whole transcriptome assay (WTA) service in human plasma samples (75F40122P00293), from Food and Drug Administration, on July 26, 2022.

On GovTribe

See Firalis's full federal record

  • Federal contract awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors